User login
Background Approval of new agents provides alternative treatment options for medical oncologists and their patients with renal cell carcinoma (RCC). Treatment decisions remain challenging in the absence of clear evidence supporting optimal selection and sequencing of treatment for different patient or tumor characteristics.
Objective To assess the clinical practice gaps of medical oncologists treating patients with RCC.
Methods Medical oncologists practicing in the United States with a case load of 1 or more RCC patient(s) a year were recruited to participate in either an online case-based survey followed by a 45-minute interview (phase 1) or a 15-minute online survey with case vignettes (phase 2). Respondents’ answers were compared with treatment guidelines and faculty experts’ recommendations.
Results Qualitative interviews (n = 27) and quantitative surveys (n = 142) were compiled. Clinical performance gaps demonstrating oncologists’ difficulties to optimally adjust their treatment plan were identified. When presented with an RCC patient with treatment-related hypertension, 34% of respondents did not select an expert-recommended option. In a scenario focused on recognizing clinical signs and symptoms as an important component of treatment decision-making, 40% of respondents agreed with the expert-recommended approach. For a progressive patient with chronic obstructive pulmonary disease, 78% of respondents were misaligned with evidence-based treatment options.
Limitations Self-selection and respondent bias may have occurred. Sample size may have limited the statistical power.
Conclusions This study identified clinically relevant performance gaps among US oncologists treating RCC patients. Education to assure familiarity with the most recent changes is needed.
Funding/sponsorship Pfizer Medical Education Group provided financial support through an educational research grant.
Click on the PDF icon at the top of this introduction to read the full article.
Background Approval of new agents provides alternative treatment options for medical oncologists and their patients with renal cell carcinoma (RCC). Treatment decisions remain challenging in the absence of clear evidence supporting optimal selection and sequencing of treatment for different patient or tumor characteristics.
Objective To assess the clinical practice gaps of medical oncologists treating patients with RCC.
Methods Medical oncologists practicing in the United States with a case load of 1 or more RCC patient(s) a year were recruited to participate in either an online case-based survey followed by a 45-minute interview (phase 1) or a 15-minute online survey with case vignettes (phase 2). Respondents’ answers were compared with treatment guidelines and faculty experts’ recommendations.
Results Qualitative interviews (n = 27) and quantitative surveys (n = 142) were compiled. Clinical performance gaps demonstrating oncologists’ difficulties to optimally adjust their treatment plan were identified. When presented with an RCC patient with treatment-related hypertension, 34% of respondents did not select an expert-recommended option. In a scenario focused on recognizing clinical signs and symptoms as an important component of treatment decision-making, 40% of respondents agreed with the expert-recommended approach. For a progressive patient with chronic obstructive pulmonary disease, 78% of respondents were misaligned with evidence-based treatment options.
Limitations Self-selection and respondent bias may have occurred. Sample size may have limited the statistical power.
Conclusions This study identified clinically relevant performance gaps among US oncologists treating RCC patients. Education to assure familiarity with the most recent changes is needed.
Funding/sponsorship Pfizer Medical Education Group provided financial support through an educational research grant.
Click on the PDF icon at the top of this introduction to read the full article.
Background Approval of new agents provides alternative treatment options for medical oncologists and their patients with renal cell carcinoma (RCC). Treatment decisions remain challenging in the absence of clear evidence supporting optimal selection and sequencing of treatment for different patient or tumor characteristics.
Objective To assess the clinical practice gaps of medical oncologists treating patients with RCC.
Methods Medical oncologists practicing in the United States with a case load of 1 or more RCC patient(s) a year were recruited to participate in either an online case-based survey followed by a 45-minute interview (phase 1) or a 15-minute online survey with case vignettes (phase 2). Respondents’ answers were compared with treatment guidelines and faculty experts’ recommendations.
Results Qualitative interviews (n = 27) and quantitative surveys (n = 142) were compiled. Clinical performance gaps demonstrating oncologists’ difficulties to optimally adjust their treatment plan were identified. When presented with an RCC patient with treatment-related hypertension, 34% of respondents did not select an expert-recommended option. In a scenario focused on recognizing clinical signs and symptoms as an important component of treatment decision-making, 40% of respondents agreed with the expert-recommended approach. For a progressive patient with chronic obstructive pulmonary disease, 78% of respondents were misaligned with evidence-based treatment options.
Limitations Self-selection and respondent bias may have occurred. Sample size may have limited the statistical power.
Conclusions This study identified clinically relevant performance gaps among US oncologists treating RCC patients. Education to assure familiarity with the most recent changes is needed.
Funding/sponsorship Pfizer Medical Education Group provided financial support through an educational research grant.
Click on the PDF icon at the top of this introduction to read the full article.